Lucid Diagnostics Inc. (LUCD) Form 10-Q — Aug 12, 2026
Lucid Diagnostics' Form 10-Q for the quarter ended June 30, 2026 discloses substantial doubt about the company's ability to continue as a going concern, with $33.4 million of cash, $9.1 million of working capital, and $23.4 million of cash used in operations during the first half. In May 2026, holders of its $21.975 million senior secured convertible notes (12% coupon, $1.00 conversion price, due November 2029) waived an event of default triggered by the failure to obtain a positive Medicare coverage decision for the EsoGuard test by May 22, 2026, but the waiver only runs through August 22, 2026.
Key figures
- Revenue
- 1474000
- Total Debt
- 21975000
- Debt Amount
- 21975000
- Revenue Yoy
- 26.7% Q2 YoY; 37.1% H1 YoY
- Total Assets
- 38946000
- Cash Position
- 33404000
- Interest Rate
- 12
- Maturity Date
- November 22, 2029
- Shares Outstanding
- 190757165
- Waiver expiry
- August 22, 2026
- H1 2025 revenue
- 1991000
- H1 2026 revenue
- 2730000
- Q2 2025 revenue
- 1163000
- Q2 2026 revenue
- 1474000
- Working capital
- 9100000
- H1 2026 net loss
- 25596000
- Atm facility capacity
- 25000000
- Minimum cash covenant
- 5000000
- Monthly msa fee pavmed
- 1050000
- Atm shares sold h1 2026
- 4161747
- Atm net proceeds h1 2026
- 5300000
- April 2026 offering shares
- 18000000
- Operating cash burn h1 2026
- 23398000
- Weighted avg shares q2 2025
- 98989161
- Weighted avg shares q2 2026
- 183124412
- Convertible notes face value
- 21975000
- Convertible notes fair value
- 23500000
- April 2026 offering net proceeds
- 16800000
- Convertible notes conversion price
- 1
- April 2026 offering price per share
- 1
- Noteholders required rate of return
- 30.90%
- Shares held in abeyance june 30 2026
- 22304671
- H1 2026 net loss attributable to common
- 38343000
- Q2 2025 net loss attributable to common
- 7888000
- Q2 2026 net loss attributable to common
- 14715000
Price after filing
Close on the filing date to close N calendar days later (from $0.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.